435 results about "Multi drug resistant" patented technology

This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.

This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.

This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.

This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.

The invention relates to an antitumor 3,5-diphenylmethylene-4-piperidone derivative and a preparation method thereof, and belongs to the technical fields of antitumor drugs and preparation methods thereof. The preparation method comprises the following steps: performing a Claisen-Schmidt condensation reaction on a 4-piperidone derivative having antitumor activity and 4-trifluoromethyl through 4-piperidone hydrochloride to obtain an intermediate a; and reacting the intermediate a with an acylation or sulfonylation reagent to obtain N-R-3,5-di(4-trifluoromethyl benzylidene)-4-piperidone b-5. The 3,5-diphenylmethylene-4-piperidone derivative is novel in structure, has the advantage of combination of a plurality of molecular targets, and has multidrug resistance activity; and the genotoxicity of currently-used antitumor drugs can be avoided. Compared with normal cells, the derivative has higher antitumor activity to tumor cells, so that the derivative has a great application prospect in the field of antitumor drugs.

Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment are provided herein. The compounds described herein are useful as anti-neoplastic agents, i.e., to inhibit tumor cell growth in vitro or in vivo, in mammalian hosts, such as humans or animals, e.g., domestic animals, and are effective against solid tumors, hematologic malignancies and multi-drug resistant cancers / tumors. The present compounds can be used alone or they can be used in combination with one or more anti-cancer or anti-tumor agents.